{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-293899","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.824940+00:00","generated_at":"2026-06-21T12:26:57.966047+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences doses first patient in Phase 1/2 SURF301 study of TYRA-300","bullets":["First patient dosed in SURF301 Phase 1/2 study of TYRA-300 for FGFR3+ advanced solid tumors.","Multi-center, open-label study to determine optimal/MTD/RP2D and evaluate antitumor activity.","Study targets both untreated and resistant FGFR3+ solid tumors; announced Nov 29, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-293899","json":"https://secwatch.observer/filing/0001193125-22-293899.json","markdown":"https://secwatch.observer/filing/0001193125-22-293899.md","text":"https://secwatch.observer/filing/0001193125-22-293899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312522293899/0001193125-22-293899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312522293899/d423130d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:26:57.966047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}